LT3001 Drug Product

Phase 2Small molecule

LLumosa Therapeutics Co., Ltd.

LT3001 Drug Product is one of 11 small molecule programs targeting Acute Ischemic Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Ischemic StrokeRecruiting

Acute Ischemic StrokePhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Acute Ischemic Stroke

#DrugCompanyPhaseTrials

Tnkase

Roche

Phase 3

6 2

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Phase 3

1 3

Epsom Salt

FFresenius Kabi USA, LLC

Phase 1

1 4

TAK-755

Takeda

Phase 2

1 5

Cerebrolysin

EEver Neuro Pharma GmbH

Phase 2

1 6

LT3001 Drug Product

LLumosa Therapeutics Co., Ltd.

Phase 2

2 7

Anisodine Hydrobromide

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2

2 8

J147

AAbrexa Pharmaceuticals, Inc.

Phase 2

1 9

Prourokinase

SSuzhou Landing Pharmaceuticals

Phase 2

1 10

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Acute Ischemic Stroke

NCT05198323

Q2 2028

Phase 2Recruiting

Acute Ischemic Stroke

NCT07890298

Clinical

Trials by Indication[1]

Acute Ischemic Stroke2 trials

An Open-Label, Single-Arm, Exploratory Study to Evaluate Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in Participants With Acute Ischemic Stroke (AIS)

Recruiting·LLumosa Therapeutics Co., Ltd.·Phase 2·NCT07890298·10 enrolled

A Phase II, Two-Part, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects With Acute Ischemic Stroke (AIS) Undergoing Endovascular Thrombectomy (EVT)

Active, not recruiting·LLumosa Therapeutics Co., Ltd.·Phase 2·NCT05198323·66 enrolled

Efficacy1 trial

A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS

Completed·LLumosa Therapeutics Co., Ltd.·Phase 2·NCT04091945·24 enrolled

Interaction1 trial

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Completed·LLumosa Therapeutics Co., Ltd.·Phase 1·NCT04809818·65 enrolled

Safety and Efficacy1 trial

A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects

Completed·LLumosa Therapeutics Co., Ltd.·Phase 2·NCT05403866·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for LT3001 Drug Product. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LT3001 Drug Product compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LT3001 Drug Product. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lumosa Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLumosa Therapeutics Co., Ltd.

LT3001 Drug Product

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2028

Trials by Indication[1]

Acute Ischemic Stroke2 trials

Efficacy1 trial

Interaction1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News